中文产业新闻精选评分67Chinese source
辉瑞TUKYSA联合曲妥珠单抗和帕妥珠单抗获FDA批准，用于HER2+乳腺癌一线维持治疗
辉瑞新型HER2+乳腺癌的组合获FDA批准，死亡风险相比曲妥珠单抗单药降低35.9%
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.
辉瑞新型HER2+乳腺癌的组合获FDA批准，死亡风险相比曲妥珠单抗单药降低35.9%
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.